The Radiation Oncology and Imaging Program (ROIP) is a comprehensive program that includes radiation biologists, imaging scientists, medical physicists, bioengineers, radiation oncologists and radiologists. In the previously funded Radiation Oncology Program (ROP), a significant number of Program members engaged in imaging research. Therefore, two years ago this Program was broadened to include an explicit emphasis on imaging in the goals, themes and activities of the ROIP. The Goals of the ROIP are to foster research interactions that stimulate the integration of basic science, bioengineering, and clinical trials: 1. to increase the local control of tumors by radiation therapy while minimizing side effects; and 2. to develop and evaluate novel imaging methods and imaging biomarkers for localized and disseminated cancer. To accomplish these goals, the Themes of the Program are: 1. to understand the mechanisms of tumor and normal tissue response to radiation; and 2. to develop and apply imaging methods for the detection and staging of cancer and for image-guided therapy and response assessment. To accomplish these goals, the ROIP sponsors several venues for interaction including a monthly seminar series and a yearly retreat. Research efforts of Program members in radiation biology and imaging have been facilitated by several multi-investigator grants including a P41 grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) that supports the Center for In Vivo Microscopy, a U19 grant from the NIAID that supports a Center for Medical Countermeasures Against Radiation, and a Program Project Grant from NASA to study radiation-induced cancer. In addition, during the previous funding cycle, S10 grants from the NCI were awarded to purchase a micro-PET and a state-of-the-art micro-CT/micro-irradiator that delivers focal, image-guided radiation therapy to small animals. Clinical and translational research are supported by dedicated clinical research MR and PET/CT scanners that are available in the Radiology and Radiation Oncology departments, as well as clinical trial managers and clinical research coordinators, who are devoted to accruing patients to clinical trials within our Program. A tumor metrics service has been developed in Radiology to support clinical trials in the Duke Cancer Institute. Clinical investigators utilize this infrastructure to undertake a number of investigator-initiated clinical trials (n=20) and cooperative group trials (n=11) within the Department of Radiation Oncology. In the Program there are 31 Primary members and 15 Secondary members across 9 departments. Members have contributed to over 700 publications during the funding period. Program members in the Department of Radiology also participate in the imaging cooperative group trials conducted by ACRIN, as well as imaging components in other cooperative group trials. Since 2009, clinical trial accrual has been 387 within the Department of Radiation Oncology. In addition, a number of the Program members are leaders of national clinical trials within cooperative groups (e.g., Radiation Therapy Oncology Group, which has now become a part of NRG, and ACRIN which has become part of ECOG-ACRIN). Total funding (Direct + Indirect) for program members was $11.8M in 2013, of which $8.2M (69%) came from peer- reviewed sources. A cancer-focus was illustrated by $3.7M from the NCI, the American Association for Cancer Research, Komen Foundation and cancer-related Department of Defense programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-43
Application #
9198522
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
43
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766

Showing the most recent 10 out of 513 publications